Key result
High depressive symptom burden was associated with increased odds of medication nonadherence for dyslipidemia (OR 1.42, P=0.03), but not for hypertension or type 2 diabetes.
Why the study?
Does high depressive symptom burden increase medication nonadherence in veterans prescribed treatments for hypertension, dyslipidemia, or type 2 diabetes?
Cross-Sectional (n=1,026)
Does high depressive symptom burden increase medication nonadherence in veterans prescribed treatments for hypertension, dyslipidemia, or type 2 diabetes?
Odds Ratio: 1.42
p-value: p=0.03
High depressive symptom burden is associated with increased self-reported nonadherence to dyslipidemia medications, driven by negative expectations and economic burden, highlighting the need for tailored adherence interventions.
Depressive symptoms associated with dyslipidemia nonadherence only; hypothesis-generating for tailored interventions, requires prospective confirmation.
OBJECTIVE: Persons with depressive symptoms generally have higher rates of medication nonadherence than persons without depressive symptoms. However, little is known about whether this association differs by comorbid medical condition or whether reasons for nonadherence differ by depressive symptoms or comorbid medical condition. METHODS: Self-reported extent of nonadherence, reasons for nonadherence, and depressive symptoms among 1,026 veterans prescribed medications for hypertension, dyslipidemia, and/or type 2 diabetes were assessed. RESULTS: In multivariable logistic regression adjusted for clinical and demographic factors, the odds of nonadherence were higher among participants with high depressive symptom burden for dyslipidemia (n=848; odds ratio [OR]: 1.42, P=0.03) but not hypertension (n=916; OR: 1.24, P=0.15), or type 2 diabetes (n=447; OR: 1.15, P=0.51). Among participants reporting nonadherence to antihypertensive and antilipemic medications, those with greater depressive symptom burden had greater odds of endorsing medication nonadherence reasons related to negative expectations and excessive economic burden. Neither extent of nonadherence nor reasons for nonadherence differed by depressive symptom burden among patients with diabetes. CONCLUSION: These findings suggest that clinicians may consider tailoring interventions to improve adherence to antihypertensive and antilipemic medications to specific medication concerns of participants with depressive symptoms.
No takes yet. Share an insight, caveat, or question.
Weidenbacher et al. (2015) conducted a cross-sectional in Hypertension, dyslipidemia, and/or type 2 diabetes (n=1,026). High depressive symptom burden vs. Lower depressive symptom burden was evaluated on Medication nonadherence for dyslipidemia (OR 1.42, p=0.03). High depressive symptom burden was associated with increased odds of medication nonadherence for dyslipidemia (OR 1.42, P=0.03), but not for hypertension or type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: